Cytophage Technologies Ltd.
CYTO.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 5.73% | -14.39% | 112.78% | ||
| Depreciation & Amortization | 53.54% | 53.08% | 64.30% | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 11.26% | -8.94% | 33.20% | ||
| Operating Income | -11.26% | 8.94% | -33.20% | ||
| Income Before Tax | -9.88% | -5.70% | -270.17% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -9.88% | -5.70% | -270.17% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -9.88% | -5.70% | -270.17% | ||
| EBIT | -11.26% | 8.94% | -33.20% | ||
| EBITDA | -13.08% | 7.36% | -39.49% | ||
| EPS Basic | 12.94% | 17.16% | -212.75% | ||
| Normalized Basic EPS | 12.26% | 16.54% | -15.63% | ||
| EPS Diluted | 12.94% | 24.22% | -200.90% | ||
| Normalized Diluted EPS | 12.26% | 16.54% | -15.63% | ||
| Average Basic Shares Outstanding | 26.18% | 27.16% | 18.33% | ||
| Average Diluted Shares Outstanding | 26.18% | 27.16% | 18.33% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||